

Coronary Artery Disease (CAD) Analytic Flowchart

General Inclusion Criteria

All face-to-face office visits with physician, physicians' assistant, or nurse practitioner occurring during the sampling period where at least two visits had a documented diagnosis of coronary artery disease (see Appendix A.1 and A.2)

AND

Patient is 18 years or older at the beginning of the measurement period

[CADCONFIRMED] = 1
(see Appendix A.1 and A.2)

AND

Beginning of measurement period –
[DATEOFBIRTH] ≥ 18

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement™ (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

© 2006 American Medical Association. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

CPT® contained in the Measures specifications is copyright 2005 American Medical Association.
LOINC® copyright 2004 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2002-2004 College of American Pathologists. All rights reserved

Measure Owner Designation
♣ AMA/PCPI is the measure owner
▲ CMS is the measure owner
■ NCQA is the measure owner

Coronary Artery Disease (CAD) Analytic Flowchart

Antiplatelet Therapy (*CAD-1): Percentage of patients who were prescribed antiplatelet therapy

Denominator: All patients with CAD \geq 18 years of age

Denominator Inclusions

All patients (each unique patient identifier equals one case in the denominator) meeting the inclusion criteria (page 1)
--

Each unique [PATIENTID] = one case in the denominator

AND

Meeting inclusion criteria (page 1)

Denominator Exclusions (Exclusions only applied if the patient did not receive antiplatelet therapy)

Any visit where- Excluded for Medical Reason(s) Excluded for Patient Reason(s) Excluded for System Reason(s) (see Appendix B.1, B.2, B.3)

[CADANTIPLATDRUG] = 3

OR

[CADANTIPLATDRUG] = 4

OR

[CADANTIPLATDRUG] = 5

(see Appendix B.1, B.2, B.3)

Numerator: Patients who were prescribed antiplatelet therapy (aspirin, clopidogrel or combination of aspirin and dipyridamole)

Numerator Inclusions

Patients who were prescribed antiplatelet therapy (see Tables 1, 2 and Appendix C.1)

[CADANTIPLATDRUG] = 1

(see Tables 1, 2 and Appendix C.1)

Coronary Artery Disease (CAD) Analytic Flowchart

Drug Therapy for Lowering LDL Cholesterol (*CAD-2): Percentage of patients who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines)

Denominator: All patients with CAD \geq 18 years of age

Denominator Inclusions

All patients (each unique patient identifier equals one case in the denominator) meeting the inclusion criteria (page 1)

Each unique [PATIENTID] = one case in the denominator

AND

Meeting inclusion criteria (page 1)

Denominator Exclusions (Exclusions only applied if the patient did not receive lipid-lowering therapy)

Any visit where-
Excluded for Medical Reason(s)
Excluded for Patient Reason(s)
Excluded for System Reason(s)
(see Appendix D.1, D.2, D.3, D.4)

[CADLDLDRUG] = 3

OR

[CADLDLDRUG] = 4

OR

[CADLDLDRUG] = 5

(see Appendix D.1, D.2, D.3, D.4)

Numerator: Patients who were prescribed lipid-lowering therapy (based on current ACC/AHA guidelines)

Numerator Inclusions

Patients who were prescribed a lipid-lowering drug
(see Table 3 and Appendix E.1)

[CADLDLDRUG] = 1

(see Table 3 and Appendix E.1)

Coronary Artery Disease (CAD) Analytic Flowchart

Beta-Blocker Therapy – Prior Myocardial Infarction (MI) (*CAD-3): Percentage of patients with prior MI at any time who were prescribed beta-blocker therapy

Denominator: All patients with CAD who also have prior MI at any time \geq 18 years of age

Denominator Inclusions

All patients (each unique patient identifier equals one case in the denominator) meeting the inclusion criteria (page 1) and those with prior MI (see Appendix F.1)

Each unique [PATIENTID] = one case in the denominator

AND

Meeting inclusion criteria (page 1)

AND

[CADMI] = 1 (see Appendix F.1)

Denominator Exclusions (Exclusions only applied if the patient did not receive beta-blocker therapy)

Any visit where-
Excluded for Medical Reason(s)
Excluded for Patient Reason(s)
Excluded for System Reason(s)
(see Appendix G.1, G.2, G.3)

[CADBBLOCKDRUG] = 3

OR

[CADBBLOCKDRUG] = 4

OR

[CADBBLOCKDRUG] = 5
(see Appendix G.1, G.2, G.3)

Numerator: Patients who were prescribed beta-blocker therapy

Numerator Inclusions

Patients who were prescribed beta-blocker therapy (see Table 4 and Appendix F.2)

[CADBBLOCKDRUG] = 1
(see Table 4 and Appendix F.2)

Coronary Artery Disease (CAD) Analytic Flowchart

Lipid Profile (*CAD-5): Percentage of patients who received at least one lipid profile (or ALL component tests)

Denominator: All patients with CAD \geq 18 years of age

Denominator Inclusions

All patients (each unique patient identifier equals one case in the denominator) meeting the inclusion criteria (page 1)

Each unique [PATIENTID] = one case in the denominator

AND

Meeting inclusion criteria (page 1)

Denominator Exclusions

None

None

Numerator: Patients who received at least one lipid profile (or ALL component tests)

Numerator Inclusions

Patients who received at least one lipid profile (or ALL component tests) (see Appendix H.1, H.2, H.3)

[CADLIPID] = 1

(see Appendix H.1, H.2, H.3)

Coronary Artery Disease (CAD) Analytic Flowchart

LDL Cholesterol Level ([^]CAD-6): Percentage of patients with most recent LDL cholesterol < 100 mg/dL

Denominator: All patients with CAD \geq 18 years of age with at least one LDL cholesterol test

Denominator Inclusions

All patients (each unique patient identifier equals one case in the denominator) meeting the inclusion criteria (page 1) and who had an LDL cholesterol completed (see Appendix I.1, I.2, I.3)

Each unique [PATIENTID] = one case in the denominator

AND

Meeting inclusion criteria (page 1)

AND

[CADLDLCTEST] = 1

(see Appendix I.1, I.2, I.3)

Denominator Exclusions

None

None

Numerator: Patients with most recent LDL cholesterol < 100 mg/dL

Numerator Inclusions

Patients with most recent LDL-C < 100 mg/dL

[CADL DLCVALUE] < 100 mg/dL

Coronary Artery Disease (CAD) Analytic Flowchart

ACE Inhibitor or ARB Therapy (*CAD-7): Percentage of patients who also have diabetes and/or LVSD who were prescribed ACE inhibitor or ARB therapy

Denominator: All patients with CAD \geq 18 years of age who also have diabetes and/or LVSD

Denominator Inclusions

All patients (each unique patient identifier equals one case in the denominator) meeting the inclusion criteria (page 1) and who also have diabetes (see Tables 5,6 and Appendix J.1) and/or LVSD (defined as left ventricular ejection fraction [LVEF] < 40% or moderately or severely depressed left ventricular systolic function) (see Appendix J.2, J.3, J.4)

Each unique [PATIENTID] = one case in the denominator
AND
 Meeting inclusion criteria (page 1)
AND
 [CADDIABETES] = 1 (see Tables 5, 6 and Appendix J.1) **AND/OR** [HFCADLVSD] = 1
 (see Appendix J.2, J.3, J.4)

Denominator Exclusions (Exclusions only applied if the patient did not receive ACE Inhibitor or ARB therapy)

Any visit where-
 Excluded for Medical Reason(s)
 Excluded for Patient Reason(s)
 Excluded for System Reason(s)
 (see Appendix K.1, K.2, K.3)

[CADACEARBDRUG] = 3
OR
 [CADACEARBDRUG] = 4
OR
 [CADACEARBDRUG] = 5
 (see Appendix K.1, K.2, K.3)

Numerator: Patients who were prescribed ACE inhibitor or ARB therapy

Numerator Inclusions

Patients who were prescribed ACE Inhibitor or ARB therapy (see Tables 7, 8 and Appendix J.5)

[CADACEARBDRUG] = 1
 (see Tables 7, 8 and Appendix J.5)